Search Results 1151-1160 of 11507 for Ibrance

  1. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  2. Neurology - Clinical trials - Mayo Clinic

    Learn more about clinical trials related to conditions of the nervous system.

  3. Non-Small Cell Lung Cancer Clinical Trials - Mayo Clinic Research

    The purpose of this study is to evaluate the effectiveness and safety of durvalumab versus placebo following Stereotactic Body Radiation Therapy (SBRT) in ...

  4. Neurosurgery - Clinical trials

    The purpose of this study is to assess the differences in microvascular anastomosis outcomes between the experiment aneurysmal subarachnoid hemorrhage (aSAH)- ...

  5. A 52-week Study Of Rilzabrutinib Efficacy And Safety Compared To Placebo In Adults Diagnosed With IgG4-related Disease - Mayo Clinic

    About this study. This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and ...

  6. Spinal cord tumor - Doctors and departments - Mayo Clinic

    Spinal cord tumors can cause serious problems such as pain and paralysis. Find out about diagnosis and treatment.

  7. Inflammatory bowel disease (IBD) - Doctors and departments - Mayo Clinic

    Long-lasting diarrhea and belly pain could be caused by inflammatory bowel disease, also called IBD. Learn about IBD causes, diagnosis and treatment.

  8. PRESERVE-Zenith® Iliac Branch Clinical Study

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  9. A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in ...

  10. Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days - Mayo Clinic

    About this study. Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients ...